Drugs / vMCO-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05417126 | Jul 2022 → Aug 2023 | Stargardt disease | Nanoscope Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vMCO-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05417126 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated virus serotype 2-based vector” NCT05417126 ↗ |
| Route | Intravitreal | “single intravitreal injection” NCT05417126 ↗ |